{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15180", "batch_size": 200, "batch_pos": 148, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "The segment describes market movement ('climbed'), which is a neutral economic trend per Q2 rules, lacking high-potency framing of the threat's impact.", "method": "llm_batch", "batch_id": "batch_2_17400", "batch_size": 200, "batch_pos": 113, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "'climbed' is similar to a moderate verb, but this describes financial metrics, which are excluded from Q3.", "method": "llm_batch", "batch_id": "batch_3_19936", "batch_size": 200, "batch_pos": 30, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_20356", "batch_size": 200, "batch_pos": 26, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "Lacks explicit calming language from the author or source.", "method": "llm_batch", "batch_id": "batch_5_13652", "batch_size": 200, "batch_pos": 20, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_9680", "batch_size": 200, "batch_pos": 172, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 7, "answer": "no", "rationale": "No bare negation found.", "method": "llm_batch", "batch_id": "batch_7_20248", "batch_size": 200, "batch_pos": 160, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 8, "answer": "yes", "rationale": "The segment describes stock movement based on a report about funding a trial ('fund a late-stage trial'), which is a development/preparedness capability, without calming keywords.", "method": "llm_batch", "batch_id": "batch_8_11804", "batch_size": 200, "batch_pos": 67, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
